A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma

NCT05064852 | Unknown

• 1 other identifier: HMPL-012-RWS-BTC101
• Study Type: observational
• Target: 200
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a prospective, single-arm, open-label,multi-center, observational real-world clinical study to observe and evaluate the efficacy and safety of Surufatinib in the treatment of patients with biliary tract cancer (BTC).

Conditions

Biliary Tract Carcinoma

Outcome Measures

Primary Outcomes (1)

• Progression-free survival (PFS)

  PFS was defined as the length of time from the administration of the first-dose until disease progression or death from any cause before disease progression.

  6 months after the last patient enrolled

Secondary Outcomes (4)

• Safty

  up to 4 weeks after the last dose

• Disease Control Rate(DCR)

  6 months after the last patient enrolled

• Overall survival (OS)

  6 months after the last patient enrolled

• Objective Response Rate (ORR)

  6 months after the last patient enrolled

Other Outcomes (2)

• QoL

  6 months after the last patient enrolled

• Biomarkers

  before the first dose

Study Arms (1)

Surufatinib

Patients with BTC visited the site from 2021 to 2023 and received Surufatinib therapy.

Drug: Surufatinib

Interventions

Surufatinib DRUG

The study is a real-world study. According to the actual medical history of patients, the usage of Surufatinib was collected.

Surufatinib

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with Biliary Tract Carcinoma

You may qualify if:

• Age ≥18, male or female;
• Patients with histologically or cytologically confirmed unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder cancer (GBC); Surgical resection with positive margins are allowed;
• ECOG score 0-2;
• Expected survival of ≥12 weeks;
• Confirmed measurable (or evaluable) lesions that meet the requirements of RECIST 1.1;
• It is not less than 7 days since the end of the last systematic treatment, and the palliative treatment of the limited area is allowed
• Treatment has been over 4 weeks;
• The function of major organs and bone marrow was basically normal;
• Fully understand this study, voluntarily participate in it, and sign the informed consent.
• Fertile male or female patients shall volunteer to use effective contraceptive methods, such as double barrier contraception, condoms, oral or injected contraceptives, and intrauterine devices, during the study period and within 90 days after the last dosing of the investigational drug. All-female patients will be considered fertile unless they have had natural menopause, or artificial menopause, or sterilization (such as hysterectomy, bilateral adnexectomy, or ovarian radiation)

You may not qualify if:

• Fine basal skin that has been diagnosed with other malignant tumors within the past 5 years and has been effectively treated (Except for cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer and breast cancer after effective resection outside);
• Receiving other investigational drugs or approved or under development antitumor therapies;
• Patients with contraindications to Surufatinib (e.g., active bleeding, ulcers, intestinal perforation, bowel)Obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, major surgery within 30 days, severe liver and kidney insufficiency, etc.);
• The patient has any current disease or condition that affects the absorption of the drug, or the patient cannot take it orally Surufatinib;
• Demonstrated allergy to any component of the test drug and/or its excipients;
• Pregnant (positive pregnancy test before dosing) or breast-feeding women;
• Patients with large pleural effusion or ascites requiring drainage;
• Taken a drug containing hyperforin perforatum within 3 weeks prior to the first study, or before taken other CYP3A4 strong inducer or inhibitor within 2 weeks;
• The investigator determined that liver metastases accounted for 50% or more of the total volume of the liver;
• Clinically intervened biliary obstruction was not in remission or required anti-infective therapy as determined by the investigator 14 days prior to the first study drug treatment;
• Previous liver transplantation;
• Clinically significant electrolyte abnormalities as determined by the investigator;
• Any other diseases with clinically significant metabolic abnormalities, abnormal physical observations, or abnormal laboratory findings, which are judged by the investigator as evidence that the patient has a disease or condition that is unsuitable for the study drug (e.g., epileptic seizures requiring treatment), or that would interfere with the interpretation of the study results, or that may put the patient at high risk.

Sponsors & Collaborators

• Qilu Hospital of Shandong University: lead

MeSH Terms

Interventions

surufatinib

Central Study Contacts

Yunfei Xu, M.D.

CONTACT

18560083735; xuyunfei1988@126.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 21, 2021
• First Posted: October 1, 2021
• Study Start: September 20, 2021
• Primary Completion: December 20, 2022
• Study Completion: December 20, 2023
• Last Updated: October 1, 2021

Record last verified: 2021-09